You have 9 free searches left this month | for more free features.

Condition

Cholangiocarcinoma (1)

Colorectal Cancer (1)

Melanoma (Skin) (1)

Metastatic Cancer (1)

Pancreatic Cancer (1)

Solid Tumor (1)

Overall Status

Recruiting (1)

Unknown status (1)

Sign in for free

Phase

phase 1 (1)

phase 1/phase 2 (1)

Sponsor

PureTech (1)

Xiangya Hospital of Central South University (1)

Collaborator

Intervention

anti-pd-1 (2)

gemcitabine/nab-paclitaxel (1)

imiquimod 5% topical cream (1)

lyt-200 (1)

peptide (1)

rhgm-csf (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Industry (1)

Other (1)

Study Type

Interventional (2)

anti-pd-1

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Metastatic Cancer, Solid Tumor, Cholangiocarcinoma Trial in United States (LYT-200, Anti-PD-1, Gemcitabine/nab-paclitaxel)

Recruiting

Metastatic Cancer
+4 more

LYT-200
+2 more

Phoenix, Arizona
+15 more

Mar 9, 2022

Melanoma (Skin) Trial in Changsha (Peptide, Anti-PD-1, rhGM-CSF)

Unknown status

Melanoma (Skin)

Peptide
+3 more

Changsha, Hunan, China

Xiangya Hospital, Central South University

Apr 24, 2020